KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Current Assets (2016 - 2025)

Nektar Therapeutics has reported Current Assets over the past 16 years, most recently at $266.3 million for Q4 2025.

  • Quarterly results put Current Assets at $266.3 million for Q4 2025, up 1.9% from a year ago — trailing twelve months through Dec 2025 was $266.3 million (up 1.9% YoY), and the annual figure for FY2025 was $266.3 million, up 1.9%.
  • Current Assets for Q4 2025 was $266.3 million at Nektar Therapeutics, down from $281.4 million in the prior quarter.
  • Over the last five years, Current Assets for NKTR hit a ceiling of $1.1 billion in Q1 2021 and a floor of $186.6 million in Q2 2025.
  • Median Current Assets over the past 5 years was $420.0 million (2023), compared with a mean of $513.5 million.
  • Biggest five-year swings in Current Assets: plummeted 39.43% in 2023 and later rose 1.9% in 2025.
  • Nektar Therapeutics' Current Assets stood at $795.6 million in 2021, then tumbled by 31.37% to $546.0 million in 2022, then plummeted by 39.43% to $330.7 million in 2023, then fell by 20.99% to $261.3 million in 2024, then grew by 1.9% to $266.3 million in 2025.
  • The last three reported values for Current Assets were $266.3 million (Q4 2025), $281.4 million (Q3 2025), and $186.6 million (Q2 2025) per Business Quant data.